Current stock price

Investor Relations

GCANRx is a publicly traded biotechnology company led by an experienced team of executives and scientists. The company is focused on the the development and commercialization of innovative Cannabinoid delivery systems.

January 30, 2020

GCAN Receives Purchase Order for 125,000 Units of its Oral Cannabis Patch from Symtomax

November 12, 2019

Greater Cannabis Company Advances CBD Study With Researchers From Israel Cannabis Research Center

October 21, 2019

Former Portugal State Secretary of Health Joins Greater Cannabis Company’s European Partner, Symtomax

Corporate Presentation

See our latest corporate presentation.

Stock Information

See our current stock performance.

Aitan Zacharin

Aitan Zacharin

CEO, Director

Mark Radom

Mark Radom

VP, General Counsel

David Tavor

David Tavor

Director, Board of Directors

Hock S. Tan

Hock S. Tan, PhD

Chairman, Scientific Advisory Board

More about our management

SEC Filings

March 30, 2020

Form NT 10-K

February 12, 2020

Form EFFECT

February 10, 2020

Form CORRESP

February 10, 2020

Form CORRESP

FAQ

What is the ticker symbol for GCANRx?

Shares of GCANRx are traded on the OTC Markets under the ticker symbol GCAN.


Where is GCANRx’s corporate headquarters?

GCANRx is based out of Baltimore, MD.


When does GCANRx’s fiscal year end?

December 31.


Who is GCANRx’s transfer agent?

Pacific Stock Transfer. 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119. (800) 785-7782. info@pacificstocktransfer.com


Who is GCANRx’s auditor?

Michael T. Studer CPA P.C. 111 West Sunrise Highway, Second Floor East Freeport, NY 11520, United State


What is GCANRx's CUSIP number?

391657103


What is GCANRx's CIK Number?

0001695473


What is GCANRx's SIC and Classification?

2834; Pharmaceutical Preparations


What is GCANRx's O/S and Float?

As of October 26, 2018 the outstanding shares are 30,846,492 and the float is approximately 13,426,759

Sign up for email alerts

Stay up to date on the latest news.